On Oct 26, major Wall Street analysts update their ratings for $ResMed (RMD.US)$, with price targets ranging from $245 to $283.
J.P. Morgan analyst David Low maintains with a buy rating, and adjusts the target price from $240 to $270.
BofA Securities analyst Lyanne Harrison maintains with a buy rating.
Jefferies analyst Matthew Taylor maintains with a hold rating, and adjusts the target price from $164 to $245.
Baird analyst David Rescott maintains with a buy rating, and adjusts the target price from $280 to $283.
Oppenheimer analyst Suraj Kalia maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $ResMed (RMD.US)$'s main analysts recently are as follows:
Following the Q1 earnings report, there is encouragement from the broad outperformance expected to begin in fiscal 2025, with a particular focus on the trends in Devices amidst ongoing GLP-1 concerns. Additionally, the company is on a path to lower its debt, thus enhancing its capital allocation flexibility.
ResMed demonstrated robust first quarter results, featuring double-digit revenue expansion across all segments, continued enhancement of gross margins, and a 35% increase in EPS. Management's outlook remains optimistic due to overall industry growth, consistent resupply activities, and prospects for further gross margin advancements.
The firm expressed growing confidence in potential upside, noting that market growth is holding steady, the company is maintaining or even expanding its market share, and is seeing advantages from the broader deployment of its AirSense 11 product.
Here are the latest investment ratings and price targets for $ResMed (RMD.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月26日，多家华尔街大行更新了$瑞思迈 (RMD.US)$的评级，目标价介于245美元至283美元。
摩根大通分析师David Low维持买入评级，并将目标价从240美元上调至270美元。
美银证券分析师Lyanne Harrison维持买入评级。
富瑞集团分析师Matthew Taylor维持持有评级，并将目标价从164美元上调至245美元。
贝雅分析师David Rescott维持买入评级，并将目标价从280美元上调至283美元。
奥本海默控股分析师Suraj Kalia维持持有评级。
此外，综合报道，$瑞思迈 (RMD.US)$近期主要分析师观点如下：
根据Q1季度收益报告，预计从2025财年开始将在所有板块表现出色，特别关注在持续的GLP-1担忧背景下的设备行业趋势。此外，公司正在降低债务，并增强其资本分配灵活性。
瑞思迈展示了强劲的第一季度业绩，各板块营业收入均实现了两位数增长，毛利率持续增加，每股收益增长了35%。管理层的展望仍然乐观，原因是整个行业的增长，持续的再供货活动，以及进一步提高毛利率的前景。
该公司对潜在收益增长表达了信恳智能，并指出市场增长保持稳定，公司正在维持甚至扩大市场份额，并从更广泛部署其AirSense 11产品中获得优势。
以下为今日5位分析师对$瑞思迈 (RMD.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
